Lymphocyte Biomarkers Predict Stem Cell Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal stem cell therapies lack effective biomarkers for predicting clinical response, making it challenging to optimize treatment outcomes for patients with tissue damage, inflammatory, and immune disorders.
Innovation Solution
Development of blood-based markers such as CD3+, CD4+, CD8+, and HLA-II levels in lymphocytes to predict clinical response to mesenchymal stem cell therapies, allowing for personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cell therapy is administered to patients with tissue damage, inflammatory, and immune disorders, then therapeutic benefits are provided through immunomodulatory capacity and paracrine effects, but there is no effective biomarker to predict clinical response, making it challenging to optimize treatment outcomes
Solution Approach 1:
The patent applies preliminary action by measuring lymphocyte biomarkers (CD3+, CD4+, CD8+, HLA-II levels) in blood samples before stem cell therapy administration. This pre-treatment assessment identifies patients likely to respond favorably, allowing clinicians to predict clinical response in advance and make informed treatment decisions before therapy begins.
Solution Approach 2:
The patent implements feedback by using lymphocyte biomarker levels as indicators that reflect the patient's immune status and predicted response to therapy. These biomarkers provide continuous information about treatment likelihood, enabling dynamic assessment and optimization of treatment strategies based on individual patient characteristics.
2Productivity
If stem cell therapy is administered without biomarker guidance, then treatment can be provided to all patients, but treatment outcomes cannot be optimized and resources may be wasted on non-responders
Solution Approach 1:
The patent applies preliminary action by performing biomarker assessment before therapy administration, identifying responders and non-responders in advance. This prevents wasting treatment time and resources on patients unlikely to benefit, thereby optimizing productivity by focusing therapy on those most likely to respond.
3Adaptability or versatility
If lymphocyte biomarkers are measured to predict clinical response, then personalized treatment approaches can be implemented, but additional testing requirements increase procedural complexity
Solution Approach 1:
The patent applies self-service by utilizing the patient's own blood sample to obtain multiple biomarker measurements (CD3+, CD4+, CD8+, HLA-II levels) through a single minimally invasive procedure. This self-contained approach using readily available patient material simplifies the overall testing process while enabling comprehensive personalized assessment.
Data Source
AI summary
The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.